Chimeric Therapeutics Ltd. ( (AU:CHM) ) has shared an announcement.
Chimeric Therapeutics announced its participation in the NWR Virtual Healthcare Conference, where CEO Dr. Rebecca McQualter will present. This engagement highlights Chimeric’s ongoing efforts to promote its pioneering cell therapy programs, which include advanced clinical trials for their CAR-T and NK cell therapies, potentially enhancing their market presence and stakeholder interest.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics is an Australian clinical-stage company specializing in cell therapy, focusing on innovative treatments for cancer. The company is a leader in the development and commercialization of autologous CAR-T and allogeneic NK cell therapies, with a diversified portfolio targeting various oncology areas through multiple clinical-stage programs.
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$7.98M
See more insights into CHM stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com